<DOC>
	<DOCNO>NCT01999933</DOCNO>
	<brief_summary>The present study randomize , control , phase II/III study early stage ( FIGO Ia2-IIb ) cervical cancer radical hysterectomy Northwest China treat radiotherapy concurrent chemoradiotherapy base surgical-pathological risk factor . All patient receive whole pelvis radiation divide three group accord adjuvant chemotherapy : concurrent chemotherapy cisplatin weekly ( 40mg/m2 ) , concurrent chemotherapy docetaxel plus cisplatin tri-weekly ( 75mg/m2 ) , concurrent adjuvant chemotherapy docetaxel plus cisplatin tri-weekly ( 75mg/m2 ) . The effectiveness , side effect evaluate accord Standard WHO response criterion , NCI common toxicity criterion adverse event ( NCI-CTC-AE ) V3.0 .</brief_summary>
	<brief_title>Evaluation Postoperative Radiotherapy Concurrent Chemotherapy Effectiveness Cervical Cancer</brief_title>
	<detailed_description>To cervical cancer patient accept radical hysterectomy , whether adjuvant therapy receive method adjuvant therapy determine postoperative pathology . In traditional opinion , postoperative risk factor divide two group : intermediate risk factor , include large tumor size , deep stromal invasion lymphovascular space invasion , high risk factor , include non-squamous cell carcinoma , marginal positive , parametric invasion pelvic lymph node ( LN ) metastasis . Patients intermediate risk factor accept adjuvant radiotherapy high risk factor receive adjuvant concurrent chemoradiotherapy . Cisplatin weekly ( 40mg/m2 ) standard regimen concurrent chemotherapy . However , retrospectively analyze 801 cervical cancer patient postoperative radiotherapy find distant metastasis main cause current treatment failure ( 84.5 % ) , suggest current regimen chemotherapy insufficient might strengthen future .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>18 Years 70 Years Histologically proven cervical cancer , FIGO stage Ia2IIb , previous chemotherapy radiotherapy Accepted radical hysterectomy 34 week Karnofsky score &gt; 70 Postoperative pathology follow risk factor : Nonsquamous cell carcinoma , deep stromal invasion , lymphovascular space invasion , marginal positive , parametria invasion , large tumor size ( tumor diameter &gt; 4cm ) pelvic LN metastasis . Patients pelvic LN metastasis combination two risk factor mention include . Examination result show radiation chemotherapy contraindication Willing accept treatment Ability comply trial requirement Postoperative residual Postoperative recurrence metastasis Without lymph node dissection Postoperative pathology show aortic lymph node metastasis Examination result show radiotherapy contraindication No indication radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Cervical cancer</keyword>
	<keyword>postoperative risk factor</keyword>
	<keyword>treatment</keyword>
</DOC>